The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the companysaid Friday, making it the first shot greenlit for use in this age group to guard against RSV. Global va...
The US Food and Drug Administration (FDA) has approved the first vaccine for respiratory syncytial virus (RSV) in the United States, the agency announced May 3. Arexvy, manufactured by GSK, is the world's first RSVvaccine for adults aged 60 years and older, the company said in an ...
Older Americans this fall could get an RSV vaccine for the first time, after the Food and Drug Administration approved Wednesday a new shot from drugmaker GSK to guard against a virus that leads to thousands of hospitalizations and deaths in seniors. "Today's approval of the first RSV vaccine...
The U.S. Food and Drug Administration on Tuesday approvedPfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease. In June, the U.S. CDCnarrowedits recommendation for the use of respiratory...
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the...
The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United ...
FDA approves RSV vaccine The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. June 8, 2024 Additional Live Streams Additional Live Streams Live ABC News Live Live Authorities investigate deadly New Year celebration terror attack in New...
The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine
The FDA has announced the approval of Ixchiq, the first licensed vaccine for chikungunya virus, for use in adults aged 18 years and older who are at increased risk of exposure.1,2 “Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for olde...